Docosahexaenoic Acid (DHA) Effects on Cognitive Function, Craving and Psychosocial Factors in Heavy Cigarette Smokers
- Conditions
- HEAVY TOBACCO SMOKERS
- Registration Number
- NCT01284660
- Lead Sponsor
- Hillel Yaffe Medical Center
- Brief Summary
The purpose of this study is to assess effects of Docosahexaenoic Acid (DHA) as an add-on novel supplement on quality of life, cognitive function, craving and psychosocial factors in heavy cigarette smokers. In humans, no previous randomized, double blind controlled study has been conducted to evaluate these effects. The aim of the study is to 1. Test Docosahexaenoic Acid (DHA) beneficial effects on objective clinical indicators of cognitive function (choice reaction time, decision making, impulsivity, facial recognition) in smokers 2. Improvement of quality of life, cigarette craving, psychosocial factors and self-perceptions in smokers treated with DHA supplement
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 51
- Nicotine dependence
- Smoked at least 10 cigarettes per day for the past 12 months and not interested in quitting
- Serious kidney, lun, neurological and cardiovascular diseases
- Suicide risk, acute psychosis, severe depression, organic brain syndromes
- Dependence on psychoactive substances other than nicotine
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Reduction in smoking urges and craving One and a half years Reduction in smoking urges and craving to be measured by the following: smoking urges and craving scales; choice reaction time, impulsivity computerized test, quality of life questionnaire, depression inventory, general health questionnaire, scale of perceived social support, facial expression task, self-esteem diary
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Bar Ilan University
🇮🇱Ramat Gan, Israel
Bar Ilan University🇮🇱Ramat Gan, Israel